The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ARGATROBAN IN 0.9% SODIUM CHLORIDE Drug Master File in Japan (ARGATROBAN IN 0.9% SODIUM CHLORIDE JDMF) empowers ARGATROBAN IN 0.9% SODIUM CHLORIDE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ARGATROBAN IN 0.9% SODIUM CHLORIDE JDMF during the approval evaluation for pharmaceutical products. At the time of ARGATROBAN IN 0.9% SODIUM CHLORIDE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ARGATROBAN IN 0.9% SODIUM CHLORIDE suppliers with JDMF on PharmaCompass.